mechanism of action of glp 1 agonists glp-1_analogs [TUSOM Glucagon-like peptide-1 receptor: mechanisms and

ASCVD, Atherosclerotic Cardiovascular Disease

In the U.S., approximately 38.4 million people, or 11.6% of the population , have diabetes, with millions more pre-diabetic or overweight, creating a large pool of potential GLP-1 users

doi: 10.1016/j.molmet.2017.11.009 32 YoungAAGedulinBRRinkTJ

CagriSema , Novo Nordisks co-formulation of semaglutide 2.4mg and the long-acting amylin analogue cagrilintide, demonstrated 22.7% body weight reduction in the REDEFINE-1 Phase 3 trial substantially exceeding standalone semaglutide and positioning Novo Nordisk to defend GLP-1 market leadership against tirzepatides superior weight loss profile

Occasional drinking occasions will still exist, but the day-to-day habitual ones (the glass of wine at home, the post-work beer) may fade